VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
KNSA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
KNSAKiniksa Pharmaceuticals International, plc
$95.05$7.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksKNSABalance Sheet

Kiniksa Pharmaceuticals International, plc (KNSA) Balance Sheet

10Y historyFree accessUpdated daily

Kiniksa carries a fortress-like capital structure with only $7.9M total debt, a 3.91 current ratio, and $710.2M equity, though liabilities have compounded 154% versus an 81% rise in assets since 2024Q2.

Income StatementBalance SheetCash FlowRatios

KNSA Balance Sheet

Annual statement

KNSA Balance Sheet

Kiniksa Pharmaceuticals International, plc (KNSA) balance sheet — 10-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16
Total Current Assets750.1M527.18M331.8M276.3M243.06M196.45M333.25M241.63M313.75M47.1M56.33M
Cash & Short-Term Investments568.76M414.07M243.63M206.37M190.61M182.2M323.48M233.38M307.3M45.55M55.97M
Cash Only81.66M165.6M183.58M107.95M122.72M122.47M114.04M46.93M307.3M45.55M55.97M
Short-Term Investments487.1M248.48M60.05M98.42M67.89M59.73M209.44M186.45M000
Accounts Receivable30.78M15.59M41.72M21.27M20.32M3.98M00000
Days Sales Outstanding8.988.435.9828.7233.6837.74-----
Inventory108.03M54.9M26.36M31.12M21.6M3.67M00000
Days Inventory Outstanding64.7465.18157.98200.97344.34147.4-----
Other Current Assets42.53M42.61M20.08M17.54M10.54M0210K06.45M105K105K
Total Non-Current Assets233.14M236.46M248.75M250.03M216.61M36.35M16.21M12.91M8.21M388K133K
Property, Plant & Equipment9.85M11.75M11.04M12.66M7.04M8.38M10.62M8.32M6.36M125K84K
Fixed Asset Turnover86.29x57.67x38.34x21.34x31.26x4.60x-----
Goodwill00000000000
Intangible Assets14.5M15.25M16.25M17.25M18.25M19.25M00000
Long-Term Investments00000000210K00
Other Non-Current Assets10.75M11.31M10.31M827K5.82M8.72M5.59M210K643K25K8K
Total Assets983.24M763.63M580.55M526.32M459.67M232.8M349.46M254.53M321.96M47.49M56.47M
Asset Turnover1.09x0.89x0.73x0.51x0.48x0.17x-----
Asset Growth %142.81%31.54%10.3%14.5%97.45%-33.38%37.3%-20.94%577.94%-15.89%-
Total Current Liabilities191.85M139.18M100.62M63.67M47.07M44.82M31.85M27.83M42.55M17.43M2.3M
Accounts Payable4.11M2.03M2.04M8.25M7.9M1.87M503K5.69M10.92M1.22M212K
Days Payables Outstanding9.062.4112.2253.25125.9374.9348.25633.7113.93K15.88K3.52K
Short-Term Debt02.99M000000000
Deferred Revenue (Current)63.62M31.81M0307K0000000
Other Current Liabilities20.26M102.36M33.12M36.91M16.97M1.54M7.74M7.11M25.96M14.64M1.1M
Current Ratio3.91x3.79x3.30x4.34x5.16x4.38x10.46x8.68x7.37x2.70x24.47x
Quick Ratio3.35x3.39x3.04x3.85x4.71x4.30x10.46x8.68x7.37x2.70x24.47x
Cash Conversion Cycle64.6671.17181.75176.44252.09110.22-----
Total Non-Current Liabilities81.19M56.84M41.5M23.82M16.46M2.94M5.68M1.28M144K119.77M79.9M
Long-Term Debt00000000000
Capital Lease Obligations21.16M6.51M7.86M10.01M2.62M2.67M4.88M955K000
Deferred Tax Liabilities000000001.22M00
Other Non-Current Liabilities45.47M18.52M1.82M1.86M1.84M270K805K326K144K119.77M79.9M
Total Liabilities273.05M196.03M142.12M87.48M63.52M47.76M37.53M29.11M42.7M137.2M82.2M
Total Debt7.88M9.5M9.86M12.26M5.92M6.05M6.99M2.65M000
Net Debt-73.78M-156.1M-173.73M-95.7M-116.8M-116.42M-107.05M-44.28M-307.3M-45.55M-55.97M
Debt / Equity0.01x0.02x0.02x0.03x0.01x0.03x0.02x0.01x---
Debt / EBITDA0.06x0.12x--0.49x------
Net Debt / EBITDA-0.56x-1.98x---9.59x------
Interest Coverage-----------
Total Equity710.19M567.61M438.44M438.84M396.15M185.04M311.94M225.42M-194.22M-89.71M-25.73M
Equity Growth %126.66%29.46%-0.09%10.78%114.09%-40.68%38.38%216.06%-116.51%-248.62%-
Book Value per Share8.367.196.146.105.632.705.044.17-6.57-2.76-0.79
Total Shareholders' Equity710.19M567.61M438.44M438.84M396.15M185.04M311.94M225.42M-194.22M-89.71M-25.73M
Common Stock21K21K20K20K19K18K18K15K13K1K1K
Retained Earnings-366.77M-462.14M-521.14M-477.95M-492.03M-675.4M-517.47M-356.09M-194.22M-91M-26.13M
Treasury Stock00000000000
Accumulated OCI-2.75M-25K-163K6K44K-66K-34K33K-4K-52K-24K
Minority Interest00000000000

Key Metrics

Growth RegimeAccelerating
ProfitabilityModerate
Balance SheetHealthy
Cash FlowRobust
Top Statement Risk

Partner profit-share obligations outpacing cash

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Self-Funded Balance Sheet Compounding

Over ten quarters, Kiniksa's total equity expanded from $435.1M to $710.2M while accumulated retained losses narrowed by roughly $133M, based on the company's quarterly balance sheets, indicating the commercial ramp is now self-funding asset growth without external capital.

Total assets nearly doubled from $542.4M to $983.2M while total debt simultaneously declined from $11.4M to $7.9M, a combination that suggests the ARCALYST ramp is absorbing growth requirements organically rather than through leverage. The fact that the D/E ratio compressed from 0.03 to 0.01 during this expansion implies improving balance sheet quality concurrent with, not in place of, the operating leverage flagged in the income statement. Investors should treat this trajectory as consistent with a business moving from capital-dependent to self-sustaining, though the pace depends on ARCALYST volume continuation.

Asset-Light Model Concentrated in Working Capital

Goodwill of $14.5M and net PPE of just $9.9M together comprise under 3% of Kiniksa's $983.2M asset base, according to the reported balance sheet, confirming an asset-light commercial model where value sits in working capital rather than fixed capital.

Net PPE drifted lower from $12.4M to $9.9M over the period even as revenue expanded roughly 160%, implying the company is essentially running off its installed base with minimal reinvestment, which aligns with the sub-0.4% capex intensity observed in cash flow statements. This profile supports high cash conversion but leaves little cushion if manufacturing or scale-up investment is later required. The steady sequential decline in goodwill from $16.8M to $14.5M warrants further investigation as either impairment or revaluation, though either interpretation would be immaterial at under 1.5% of total assets.

Equity Growth Partly Non-Cash in Nature

Equity's $275M expansion since 2024Q2 appears only partly earnings-driven, as accumulated retained losses still stand at -$366.8M, and per Kiniksa's filings stock-based compensation reached $13.1M in 2026Q3, suggesting a meaningful share of book value growth stems from non-cash issuance.

Retained losses narrowed materially from -$521.1M at 2024Q4 to -$366.8M at 2026Q3, confirming genuine earned-capital accumulation since the 2025Q1 profitability inflection rather than a balance sheet propped up by capital raises. However, the residual gap between the $275M equity build and the $154M of retained-loss recovery implies common stock and APIC additions are doing real work, and with SBC rising from $3.9M to $13.1M quarterly, investors should monitor whether issuance is diluting per-share claims on the growing asset base. The absence of meaningful buybacks means this dilution is not being offset on the repurchase line.

Ample Buffer Despite Cash Drawdown

Kiniksa's current ratio held at 3.91 in 2026Q3 even as cash fell to $81.7M from $190.0M two quarters earlier, according to reported balance sheets, yet with only $7.9M of total debt the near-term obligation burden remains negligible.

The cash decline of roughly $108M from the 2026Q1 peak occurred alongside rising liabilities, so the composition of that outflow—whether partner profit-share settlements, operating investment, or working capital timing—warrants scrutiny even though free cash flow was positive in the same period. Importantly, the current ratio has actually improved from 3.24 to 3.91 across the ten quarters, indicating current assets are growing faster than current liabilities and the liquidity cushion is not eroding on a relative basis. With D/E at 0.01 and no refinancing wall evident, the company's shock absorption appears to come from working capital flexibility rather than cash stock alone.

Deferred Revenue Signals Partner Dependency

Deferred revenue of $31.8M in 2026Q3, down sharply from $63.6M in the prior quarter but still nearly triple the $11.8M carried in 2024Q2, as disclosed in Kiniksa's balance sheets, signals collaboration-related obligations that may flatter near-term revenue visibility.

The alternating $31.8M and $63.6M pattern across recent quarters suggests deferred balances are driven by episodic collaboration milestones rather than a steady stream of prepayments from ARCALYST demand, which would make this a lumpy rather than reliable leading indicator. The tripling of the balance versus 2024 does indicate expanding partner commitments, but the quarter-to-quarter volatility means investors should not read sequential changes as a directional demand signal. Because this sits on the liability side, its eventual recognition will inflate reported revenue without corresponding incremental cash, a nuance relevant when reconciling the top-line acceleration noted in the income statement review.

Liabilities Compounding Faster Than Assets

Total liabilities grew 154% to $273.1M since 2024Q2 versus an 81% rise in assets, while cash slipped to $81.7M, as shown in Kiniksa's quarterly reports, suggesting obligations are compounding faster than the liquid buffer despite a comfortable 3.91 current ratio.

Because debt is nearly absent at $7.9M, the liability build is necessarily operating in character—plausibly accrued profit-share obligations to Regeneron, payables, and collaboration deferrals—meaning headline leverage metrics of 0.01 D/E understate the true claims ranking ahead of shareholders. The current ratio masks this because current assets have been inflated by the same working-capital dynamics driving payables growth, so the quality of that 3.91 figure depends on receivable collectability and inventory posture rather than cash alone. Given cash now sits 18% below its 2024Q2 level while obligations have more than doubled, the interplay between partner settlements and the cash position is the balance sheet item most likely to surprise investors if ARCALYST growth decelerates.

KNSA — Frequently Asked Questions

Quick answers to the most common questions about buying KNSA stock.

What are the total assets of Kiniksa Pharmaceuticals International, plc (KNSA)?

As of 2025, Kiniksa Pharmaceuticals International, plc (KNSA) had total assets of $763.6M including $527.2M in current assets.

How much debt does Kiniksa Pharmaceuticals International, plc (KNSA) have?

Kiniksa Pharmaceuticals International, plc (KNSA) carries total debt of $9.5M, offset by $414.1M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Kiniksa Pharmaceuticals International, plc?

Kiniksa Pharmaceuticals International, plc (KNSA) has total shareholders' equity (book value) of $567.6M ($7.19 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Kiniksa Pharmaceuticals International, plc's current ratio and liquidity?

Kiniksa Pharmaceuticals International, plc (KNSA) reported a current ratio of 3.79x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.